Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells

Authors: Gemma Aragonès, Paula Saavedra, Mercedes Heras, Anna Cabré, Josefa Girona, Lluís Masana

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

Recent studies have shown that fatty acid-binding protein 4 (FABP4) plasma levels are associated with impaired endothelial function in type 2 diabetes (T2D). In this work, we analysed the effect of FABP4 on the insulin-mediated nitric oxide (NO) production by endothelial cells in vitro.

Methods

In human umbilical vascular endothelial cells (HUVECs), we measured the effects of FABP4 on the insulin-mediated endothelial nitric oxide synthase (eNOS) expression and activation and on NO production. We also explored the impact of exogenous FABP4 on the insulin-signalling pathway (insulin receptor substrate 1 (IRS1) and Akt).

Results

We found that eNOS expression and activation and NO production are significantly inhibited by exogenous FABP4 in HUVECs. FABP4 induced an alteration of the insulin-mediated eNOS pathway by inhibiting IRS1 and Akt activation. These results suggest that FABP4 induces endothelial dysfunction by inhibiting the activation of the insulin-signalling pathway resulting in decreased eNOS activation and NO production.

Conclusion

These findings provide a mechanistic linkage between FABP4 and impaired endothelial function in diabetes, which leads to an increased cardiovascular risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boord JB, Fazio S, Linton MF: Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol. 2002, 13 (2): 141-147. 10.1097/00041433-200204000-00005.CrossRefPubMed Boord JB, Fazio S, Linton MF: Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol. 2002, 13 (2): 141-147. 10.1097/00041433-200204000-00005.CrossRefPubMed
2.
go back to reference Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, Hamsten A, Arner P: Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001, 44 (10): 1268-1273. 10.1007/s001250100643.CrossRefPubMed Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, Hamsten A, Arner P: Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001, 44 (10): 1268-1273. 10.1007/s001250100643.CrossRefPubMed
3.
go back to reference Fisher RM, Thorne A, Hamsten A, Arner P: Fatty acid binding protein expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals. Mol Cell Biochem. 2002, 239 (1–2): 95-100.CrossRefPubMed Fisher RM, Thorne A, Hamsten A, Arner P: Fatty acid binding protein expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals. Mol Cell Biochem. 2002, 239 (1–2): 95-100.CrossRefPubMed
4.
go back to reference Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS: Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006, 52 (3): 405-413. 10.1373/clinchem.2005.062463.CrossRefPubMed Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS: Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006, 52 (3): 405-413. 10.1373/clinchem.2005.062463.CrossRefPubMed
5.
go back to reference Cabre A, Lazaro I, Cofan M, Jarauta E, Plana N, Garcia-Otín AL, Ascaso JF, Ferré R, Civeira F, Ros E, Masana L: FABP4 plasma levels are increased in familial combined hyperlipidemia. J Lipid Res. 2010, 51 (5): 1173-1178. 10.1194/jlr.M900066.PubMedCentralCrossRefPubMed Cabre A, Lazaro I, Cofan M, Jarauta E, Plana N, Garcia-Otín AL, Ascaso JF, Ferré R, Civeira F, Ros E, Masana L: FABP4 plasma levels are increased in familial combined hyperlipidemia. J Lipid Res. 2010, 51 (5): 1173-1178. 10.1194/jlr.M900066.PubMedCentralCrossRefPubMed
6.
go back to reference Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 2007, 195 (1): e150-e158. 10.1016/j.atherosclerosis.2007.04.045.CrossRefPubMed Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 2007, 195 (1): e150-e158. 10.1016/j.atherosclerosis.2007.04.045.CrossRefPubMed
7.
go back to reference Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem. 2008, 54 (1): 181-187.CrossRefPubMed Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem. 2008, 54 (1): 181-187.CrossRefPubMed
8.
go back to reference Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res. 2008, 49 (8): 1746-1751. 10.1194/jlr.M800102-JLR200.CrossRefPubMed Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L: Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res. 2008, 49 (8): 1746-1751. 10.1194/jlr.M800102-JLR200.CrossRefPubMed
9.
go back to reference Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragones G, Parra S, Girona J, Masana L: The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis. 2008, 199 (1): 147-153. 10.1016/j.atherosclerosis.2007.09.032.CrossRefPubMed Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragones G, Parra S, Girona J, Masana L: The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis. 2008, 199 (1): 147-153. 10.1016/j.atherosclerosis.2007.09.032.CrossRefPubMed
10.
go back to reference Stejskal D, Karpisek M: Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?. Eur J Clin Invest. 2006, 36 (9): 621-625. 10.1111/j.1365-2362.2006.01696.x.CrossRefPubMed Stejskal D, Karpisek M: Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?. Eur J Clin Invest. 2006, 36 (9): 621-625. 10.1111/j.1365-2362.2006.01696.x.CrossRefPubMed
11.
go back to reference Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007, 115 (12): 1537-1543. 10.1161/CIRCULATIONAHA.106.647503.CrossRefPubMed Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007, 115 (12): 1537-1543. 10.1161/CIRCULATIONAHA.106.647503.CrossRefPubMed
12.
go back to reference Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CHK, Chau MT, Lam KS: Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27 (8): 1796-1802. 10.1161/ATVBAHA.107.146274.CrossRefPubMed Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CHK, Chau MT, Lam KS: Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27 (8): 1796-1802. 10.1161/ATVBAHA.107.146274.CrossRefPubMed
13.
go back to reference Hong J, Gu W, Zhang Y, Yan Q, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G: Different association of circulating levels of adipocyte and epidermal fatty acid-binding proteins with metabolic syndrome and coronary atherosclerosis in Chinese adults. Atherosclerosis. 2011, 217 (1): 194-200. 10.1016/j.atherosclerosis.2011.03.002.CrossRefPubMed Hong J, Gu W, Zhang Y, Yan Q, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G: Different association of circulating levels of adipocyte and epidermal fatty acid-binding proteins with metabolic syndrome and coronary atherosclerosis in Chinese adults. Atherosclerosis. 2011, 217 (1): 194-200. 10.1016/j.atherosclerosis.2011.03.002.CrossRefPubMed
14.
go back to reference Doi M, Miyoshi T, Hirohata S, Nakamura K, Usui S, Takeda K, Iwamoto M, Kusachi S, Kusano K, Ito H: Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol. 2011, 10: 44-10.1186/1475-2840-10-44.PubMedCentralCrossRefPubMed Doi M, Miyoshi T, Hirohata S, Nakamura K, Usui S, Takeda K, Iwamoto M, Kusachi S, Kusano K, Ito H: Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol. 2011, 10: 44-10.1186/1475-2840-10-44.PubMedCentralCrossRefPubMed
15.
go back to reference Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck W, Ehrhart-Bornstein M, Bornstein SR, Morano I: Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res. 2009, 105 (4): 326-334. 10.1161/CIRCRESAHA.109.200501.CrossRefPubMed Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck W, Ehrhart-Bornstein M, Bornstein SR, Morano I: Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res. 2009, 105 (4): 326-334. 10.1161/CIRCRESAHA.109.200501.CrossRefPubMed
16.
go back to reference Aragones G, Ferre R, Lazaro I, Cabre A, Plana N, Merino J, Heras M, Girona J, Masana L: Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis. 2010, 213 (1): 329-331. 10.1016/j.atherosclerosis.2010.07.026.CrossRefPubMed Aragones G, Ferre R, Lazaro I, Cabre A, Plana N, Merino J, Heras M, Girona J, Masana L: Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis. 2010, 213 (1): 329-331. 10.1016/j.atherosclerosis.2010.07.026.CrossRefPubMed
17.
go back to reference Aragonès G, Ferré R, Girona J, Plana N, Merino J, Heras M, Masana L: Small artery dilation and endothelial markers in cardiovascular risk patients. Eur J Clin Invest. 2012, 42 (1): 34-41. 10.1111/j.1365-2362.2011.02553.x.CrossRefPubMed Aragonès G, Ferré R, Girona J, Plana N, Merino J, Heras M, Masana L: Small artery dilation and endothelial markers in cardiovascular risk patients. Eur J Clin Invest. 2012, 42 (1): 34-41. 10.1111/j.1365-2362.2011.02553.x.CrossRefPubMed
18.
go back to reference Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352 (16): 1685-1695. 10.1056/NEJMra043430.CrossRefPubMed Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352 (16): 1685-1695. 10.1056/NEJMra043430.CrossRefPubMed
19.
go back to reference Jansson PA: Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med. 2007, 262 (2): 173-183. 10.1111/j.1365-2796.2007.01830.x.CrossRefPubMed Jansson PA: Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med. 2007, 262 (2): 173-183. 10.1111/j.1365-2796.2007.01830.x.CrossRefPubMed
20.
go back to reference Tabit CE, Chung WB, Hamburg NM, Vita JA: Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010, 11 (1): 61-74. 10.1007/s11154-010-9134-4.PubMedCentralCrossRefPubMed Tabit CE, Chung WB, Hamburg NM, Vita JA: Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010, 11 (1): 61-74. 10.1007/s11154-010-9134-4.PubMedCentralCrossRefPubMed
21.
go back to reference Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR: The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest. 2003, 111 (9): 1373-1380.PubMedCentralCrossRefPubMed Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR: The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest. 2003, 111 (9): 1373-1380.PubMedCentralCrossRefPubMed
22.
go back to reference Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM: Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011, 162 (7): 1564-1576. 10.1111/j.1476-5381.2010.01158.x.PubMedCentralCrossRefPubMed Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM: Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011, 162 (7): 1564-1576. 10.1111/j.1476-5381.2010.01158.x.PubMedCentralCrossRefPubMed
23.
go back to reference Lan H, Cheng CC, Kowalski TJ, Pang L, Shan L, Chuang CC, Jackson J, Rojas-Triana A, Bober L, Liu L, Voigt J, Orth P, Yang X, Shipps GW, Hedrick JA: Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity. J Lipid Res. 2011, 52 (4): 646-656. 10.1194/jlr.M012757.PubMedCentralCrossRefPubMed Lan H, Cheng CC, Kowalski TJ, Pang L, Shan L, Chuang CC, Jackson J, Rojas-Triana A, Bober L, Liu L, Voigt J, Orth P, Yang X, Shipps GW, Hedrick JA: Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity. J Lipid Res. 2011, 52 (4): 646-656. 10.1194/jlr.M012757.PubMedCentralCrossRefPubMed
24.
go back to reference Hresko RC, Hoffman RD, Flores-Riveros JR, Lane MD: Insulin receptor tyrosine kinase-catalyzed phosphorylation of 422(aP2) protein. Substrate activation by long-chain fatty acid. J Biol Chem. 1990, 265 (34): 21075-21085.PubMed Hresko RC, Hoffman RD, Flores-Riveros JR, Lane MD: Insulin receptor tyrosine kinase-catalyzed phosphorylation of 422(aP2) protein. Substrate activation by long-chain fatty acid. J Biol Chem. 1990, 265 (34): 21075-21085.PubMed
25.
go back to reference Nielsen SU, Spener F: Fatty acid-binding protein from rat heart is phosphorylated on Tyr19 in response to insulin stimulation. J Lipid Res. 1993, 34 (8): 1355-1366.PubMed Nielsen SU, Spener F: Fatty acid-binding protein from rat heart is phosphorylated on Tyr19 in response to insulin stimulation. J Lipid Res. 1993, 34 (8): 1355-1366.PubMed
26.
go back to reference Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996, 98 (4): 894-898. 10.1172/JCI118871.PubMedCentralCrossRefPubMed Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996, 98 (4): 894-898. 10.1172/JCI118871.PubMedCentralCrossRefPubMed
27.
go back to reference Burton PB, Hogben CE, Joannou CL, Clark AG, Hsuan JJ, Totty NF, Sorensen C, Evans RW, Tynan MJ: Heart fatty acid binding protein is a novel regulator of cardiac myocyte hypertrophy. Biochem Biophys Res Commun. 1994, 205 (3): 1822-1828. 10.1006/bbrc.1994.2882.CrossRefPubMed Burton PB, Hogben CE, Joannou CL, Clark AG, Hsuan JJ, Totty NF, Sorensen C, Evans RW, Tynan MJ: Heart fatty acid binding protein is a novel regulator of cardiac myocyte hypertrophy. Biochem Biophys Res Commun. 1994, 205 (3): 1822-1828. 10.1006/bbrc.1994.2882.CrossRefPubMed
28.
go back to reference Karbek B, Ozbek M, Bozkurt NC, Ginis Z, Güngünes A, Ünsal IÖ, Cakal E, Delibası T: Heart-type fatty acid binding protein (H-FABP): relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with ımpaired glucose metabolism. Cardiovasc Diabetol. 2011, 10: 37-10.1186/1475-2840-10-37.PubMedCentralCrossRefPubMed Karbek B, Ozbek M, Bozkurt NC, Ginis Z, Güngünes A, Ünsal IÖ, Cakal E, Delibası T: Heart-type fatty acid binding protein (H-FABP): relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with ımpaired glucose metabolism. Cardiovasc Diabetol. 2011, 10: 37-10.1186/1475-2840-10-37.PubMedCentralCrossRefPubMed
29.
go back to reference Fu Y, Luo L, Luo N, Garvey WT: Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis. 2006, 188 (1): 102-111. 10.1016/j.atherosclerosis.2005.10.041.CrossRefPubMed Fu Y, Luo L, Luo N, Garvey WT: Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis. 2006, 188 (1): 102-111. 10.1016/j.atherosclerosis.2005.10.041.CrossRefPubMed
Metadata
Title
Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells
Authors
Gemma Aragonès
Paula Saavedra
Mercedes Heras
Anna Cabré
Josefa Girona
Lluís Masana
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-72

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue